OTO Biotech is a Cornell-backed, IND-enabling stage biotech company building a barrier-agnostic, inflammation-targeted drug delivery platform. Our core innovation leverages the natural migratory power of neutrophils to actively transport therapeutic-loaded liposomes across biological barriers, enabling local, needle-free delivery without systemic exposure.